The strategies involved in the development of therapeutics for neurodegenerative disorders
are very complex and challenging due to the existence of the blood-brain barrier (BBB), a …

While the root causes for individual neurodegenerative diseases are distinct, many shared
pathological features and mechanisms contribute to neurodegeneration across diseases …

The discovery of various noncoding RNAs (ncRNAs) and their biological implications is a
growing area in cell biology. Increasing evidence has revealed canonical and noncanonical …

Parkinson's disease (PD) is a disabling neurodegenerative disease that manifests with
resting tremor, bradykinesia, rigidity and postural instability. Since the discovery of …

Parkinson's disease (PD) is a severely debilitating neurodegenerative disease, affecting the
motor system, leading to resting tremor, cogwheel rigidity, bradykinesia, walking and gait …

Parkinson's disease (PD) is the second most common neurodegenerative disorder, with a
documented significant increase in its prevalence in the past three decades. Both …

Parkinson's disease (PD) is the second most common neurodegenerative disorder
worldwide. Its main neuropathological hallmarks are the degeneration of dopaminergic …

Despite the wide research going on in Parkinson's disease (PD), the burden of PD still
remains high and continues to increase. The current drugs available for the treatment of PD …

Nilotinib is a broad‐based tyrosine kinase inhibitor with the highest affinity to inhibit Abelson
(c‐Abl) and discoidin domain receptors (DDR 1/2). Preclinical evidence indicates that …

Objective MicroRNA (miRNA)‐mediated (dys) regulation of gene expression has been
implicated in Parkinson's disease (PD), although results of miRNA expression studies …